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LETTER TO THE EDITOR Open Access
The diagnostic performance of patient
symptoms in screening for COPD
Kate M. Johnson1 , Wan C. Tan2, Jean Bourbeau3, Don D. Sin2,5, Mohsen Sadatsafavi1,4,5*, for the Canadian Cohort
of Obstructive Lung Disease (CanCOLD) study and the Canadian Respiratory Research Network
Abstract
It is recommended that screening for COPD be restricted to symptomatic individuals, but supporting evidence is
lacking. We determined the performance of wheeze, cough, phlegm, and dyspnea in discriminating COPD versus
non-COPD in a population-based sample of 1332 adults. Area Under the Receiver Operating Curves (AUC) indicated
that symptoms had modest performance whether assessed individually (AUCs 0.55–0.62), or in combination (AUC for
number of symptoms as the predictor 0.64). AUC improved with the inclusion of multiple other factors (AUC 0.71).
Restricting screening to symptomatic individuals is unlikely to substantially improve the yield of general population
screening for undiagnosed COPD.
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Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a com-
mon inflammatory lung condition that is characterized by
symptoms of shortness of breath, cough, and sputum pro-
duction [1]. Although COPD is under-diagnosed in the
community [2], several major guidelines, including from
the influential US Preventive Services Task Force, have rec-
ommended against the use of spirometry to screen for
COPD in asymptomatic individuals in the general popula-
tion because the number-needed-to-screen (NNS) to pre-
vent adverse disease outcomes is prohibitively large [3, 4].
Some have advocated for case finding strategies to im-
prove the diagnosis rate in the community in a more
cost-effective manner, for example by targeting spirom-
etry only among symptomatic individuals [5]. However,
many patients with undiagnosed COPD have mild disease
and may have few (if any) respiratory symptoms [6], and
individuals without COPD can experience symptoms
similar to those of COPD patients [7]. In addition, symp-
tomatic COPD patients tend to be diagnosed earlier [6]
and are therefore removed from the pool of cases that
would be detected through a screening program. We
determined the diagnostic performance of patient symp-
toms for screening in the general population to assess
whether the yield of screening could be improved by
restricting it to the symptomatic population.
Methods
We used data from the Canadian Cohort of Obstructive
Lung Disease (CanCOLD) Study. CanCOLD was a pro-
spective cohort study of 1332 adults ≥40 years who were
sampled from the general Canadian population with multi-
level sampling to ensure representativeness. Participants
were followed for a maximum of 3 years with visits at
18-month intervals [8]. They reported their demographic
information, smoking status and history, comorbidities,
and respiratory symptoms at each visit using validated
questionnaires. Diagnostic spirometry was performed at
each visit and persistent airflow limitation was defined as
post-bronchodilator FEV1/FVC < lower limit of normal.
Participants were deemed to have undiagnosed COPD if
they had persistent airflow limitation but did not report
previous physician-diagnosed COPD, emphysema, or
chronic bronchitis. Subjects with a previous diagnosis
of COPD were excluded. Information was collected on
the frequency or severity of cough, phlegm, and wheeze
using three questions for each symptom. The responses
were coded as a variable ranging from 0 to 3 for each
symptom. Breathlessness was measured using the Medical
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Research Council dyspnea scale. We also assessed the
total number of symptoms experienced by each partici-
pant (0–4 range).
First, we determined the independent associations be-
tween individual symptoms and the presence of undiag-
nosed COPD (v. no COPD) using a logistic regression
model with symptoms as separate independent variables
and adjusting for participant demographics, comorbidities,
smoking status, and pack-years. Second, we assessed the
diagnostic performance of symptoms when used individu-
ally to distinguish patients with undiagnosed COPD from
non-COPD subjects. We evaluated the sensitivity and spe-
cificity of each symptom at different thresholds (i.e., 0, 1, 2,
or 3) for defining a patient as symptomatic. We fitted
Receiver Operating Characteristic (ROC) curves to deter-
mine the Area Under the Curve (AUC) for each symptom
individually, as well as their combined performance using
the total number of symptoms. Finally, we used the AUC
of the above-mentioned logistic regression model to assess
the performance of all individual symptoms and covariates
together. An AUC of 0.5 indicates the model has no dis-
criminatory ability. Generalized estimating equations were
used in all models to account for clustering of observa-
tions within individuals.
Ethics approval for CanCOLD was obtained from the
relevant institutional review board at each study site.
Written informed consent was obtained from all partic-
ipants prior to study entry.
Results
The mean age of the sample was 67.4 years [SD 9.7],
44% were females, and 40% of the participants had three
study visits. The overall prevalence of undiagnosed COPD
was 26%; 95% had mild to moderate disease based on the
GOLD spirometric grading system [1]. The regression
model indicated that reporting wheeze, dyspnea, and cough
on most days were independently related to the presence of
undiagnosed COPD (Table 1). However, symptoms alone
had poor performance in identifying patients with undiag-
nosed COPD. Almost all symptoms, regardless of the sever-
ity, had sensitivities and positive predictive values less than
50% (Table 2).
If screening was applied to the general population (a
“blind” screening approach), the NNS to detect one
COPD case would be 3.8. If screening was restricted to
individuals who reported symptoms, the NNS would be
3.0, but compared with the “blind” approach, an additional
17% of individuals with persistent airflow limitation would
be missed.
The ROC curves indicated that wheeze had the best
performance among all symptoms (AUC = 0.62), followed
by cough and dyspnea (each AUC = 0.57), and phlegm
(AUC= 0.55). The total number of symptoms performed
marginally better than any symptom alone (AUC= 0.64).
AUC improved by ~ 0.06 when each of the symptoms was
combined with smoking history (measured as pack-years),
resulting in an AUC of 0.67 for a model that included
wheeze and pack-years. The model that included all indi-
vidual symptoms and covariates improved the AUC to
0.71 (Fig. 1).
Discussion
Our results indicate that symptoms are relatively poor at
discriminating undiagnosed COPD patients from non-
COPD subjects in a general population. The use of symp-
toms for screening is unlikely to significantly improve the
diagnostic yield compared with “blind” screening in the
general population. These data highlight the apparent
paradox in finding strong associations between symptoms
Table 1 Association between symptoms and other patient
characteristics with the odds of having undiagnosed COPD
(v. no COPD)
OR 95% CI p-value
Cough
1 (vs.0) 1.08 0.86–1.36 0.49
2 (vs.0) 1.38 0.93–2.04 0.11
3 (vs.0) 1.35 1.09–1.68 0.01
Wheeze
1 (vs.0) 1.34 1.03–1.73 0.03
2 (vs.0) 1.74 1.38–2.20 < 0.01
3 (vs.0) 1.77 0.93–3.38 0.08
Phlegm
1 (vs.0) 1.21 0.89–1.66 0.23
2 (vs.0) 1.35 0.77–2.36 0.30
3 (vs.0) 1.24 0.93–1.65 0.14
Dyspnea
2 (vs.1) 1.26 1.05–1.50 0.01
3 (vs.1) 2.05 1.30–3.22 < 0.01
4 (vs.1) 1.52 0.76–3.03 0.24
5 (vs.1) 3.35 1.88–5.97 < 0.01
Agea 0.83 0.74-0.94 < 0.01
Female (vs. male) 1.03 0.81–1.30 0.82
BMIa 0.78 0.68-0.89 < 0.01
Caucasian (vs. non-Caucasian) 2.39 1.28–4.48 0.01
Comorbidities
1 comorbidity (vs. 0) 0.93 0.76–1.14 0.51
2 comorbidities (vs. 0) 0.75 0.48–1.18 0.21
Smoking between visits (vs. no) 1.16 0.96–1.41 0.13
Smoking Pack-Years
20–40 (vs. < 20) 2.09 1.53–2.86 < 0.01
> 40 (vs. < 20) 3.09 2.22–4.32 < 0.01
BMI body mass index, CI confidence interval, OR odds ratio
aVariables were converted to z-scores in the regression model
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Table 2 Prevalence of each symptom severity category in the whole population (‘Prev’) across all study visits, and the prevalence of
undiagnosed COPD (‘COPD+’) within that symptom severity category. Sensitivity (‘TP’), specificity (‘TN’), positive predictive value
(‘PPV’), and negative predictive value (‘NPV’) of each symptom when used alone to classify undiagnosed COPD (v. no COPD) using
different severity thresholds
Symptom severity Cougha Wheezeb Phlegmc Dyspnead Total Symptomse
Prev, COPD+ Prev, COPD+ Prev, COPD+ Prev, COPD+ Prev, COPD+
0 72, 23% 78, 21% 83, 24% 70, 23% 45, 17%
1 12, 29% 10, 42% 6, 30% 26, 33% 29, 28%
2 3, 35% 10, 49% 1, 47% 3, 56% 16, 33%
3 13, 42% 2, 51% 9, 39% 1, 30% 7, 50%
4 < 1, 67% 4, 52%
TP, TN
PPV, NPV
TP, TN
PPV, NPV
TP, TN
PPV, NPV
TP, TN
PPV, NPV
TP, TN
PPV, NPV
0 vs. > 0 37, 76%
36, 77%
39, 84%
46, 79%
24, 85%
37, 76%
40, 74%
35, 77%
71, 50%
34, 83%
≤1 vs. > 1 24, 88%
41, 76%
23, 91%
49, 77%
16, 91%
40, 75%
7, 98%,
52, 75%
41, 78%
40, 79%
≤2 vs. > 2 21, 90%
42, 76%
4, 99%
51, 74%
14, 92%
39, 75%
1, 99%,
38, 74%
21, 93%
51, 77%
≤3 vs. > 3 < 1, > 99%
67, 74%
7, 98%
52, 75%
Prev prevalence, COPD+ undiagnosed COPD, TP true positive (sensitivity), TN true negative (specificity), PPV positive predictive value, NPV negative predictive value
Patients were asked, since your last visit:
a1) Do you usually cough when you don’t have a cold? 1a) Are there months you cough most days? 1b) Do you cough most days for as much as 3 months?
b2) Have you had any wheezing or whistling in your chest? 2a) Do you only have wheezing or whistling when you have a cold? 2b) Have you had an
attack of wheezing or whistling that made you short of breath?
c3) Do you usually have phlegm in your chest when you don’t have a cold? 3a) Are there months you have phlegm most days? 3b) Do you hav e
phlegm most days for as many as 3 months?
dScores on the Medical Research Council (MRC) Dyspnea scale are subtracted by 1
eThe sum of the number of individual symptoms that participants reported
Fig. 1 Receiver operating characteristic (ROC) curves for a model with all of the symptoms and covariates included (‘All variables’), as well as for
each of the symptoms individually and the total number of symptoms reported by study participants (‘Total symptoms’)
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and undiagnosed COPD, yet poor diagnostic performance
when symptoms are used to diagnose these “hidden”
COPD cases. This observation is consistent with the
well-established notion that a predictor can be strongly as-
sociated with an outcome while still being a poor classifier
of that outcome [9]. Association models are useful for
evaluating relationships at the population level, but
classification models are more relevant to decisions at an
individual level, specifically whether a test (e.g., the presence
of a symptom) can detect the underlying disease state
(e.g., undiagnosed COPD).
Previous studies have evaluated the merits of opportun-
istic case detection based on patient characteristics at the
point of care [10, 11]. They generally found that patient
characteristics and symptoms have modest capacity in de-
tecting undiagnosed COPD [10–12]. A unique feature of
our study is its population-based sample, which provides
new evidence on whether the yield of population-based
screening can be improved if symptoms are considered in
the inclusion criterion (e.g., through advertisements for
referral of symptomatic individuals for lung function
testing). Although the costs and benefits of early interven-
tion between symptomatic and asymptomatic patients were
not considered here, our results do not support the use of
symptoms in “case finding” for COPD. Symptoms should
be used in conjunction with other characteristics such as
pack-years of smoking to improve the diagnostic perform-
ance. Future studies should evaluate the cost-effectiveness
of this approach considering the long-term outcomes asso-
ciated with earlier diagnosis of COPD.
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